|Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection.|
|PMID: 22003054 Owner: NLM Status: MEDLINE|
|The Mas receptor is a class I G-protein-coupled receptor that is expressed in brain, testis, heart, and kidney. The intracellular signaling pathways activated downstream of Mas are still largely unknown. In the present study, we examined the expression pattern and signaling of Mas in the heart and assessed the participation of Mas in cardiac ischemia-reperfusion injury. Mas mRNA and protein were present in all chambers of human hearts, with cardiomyocytes and coronary arteries being sites of enriched expression. Expression of Mas in either HEK293 cells or cardiac myocytes resulted in constitutive coupling to the G(q) protein, which in turn activated phospholipase C and caused inositol phosphate accumulation. To generate chemical tools for use in probing the function of Mas, we performed a library screen and chemistry optimization program to identify potent and selective nonpeptide agonists and inverse agonists. Mas agonists activated G(q) signaling in a dose-dependent manner and reduced coronary blood flow in isolated mouse and rat hearts. Conversely, treatment of isolated rat hearts with Mas inverse agonists improved coronary flow, reduced arrhythmias, and provided cardioprotection from ischemia-reperfusion injury, an effect that was due, at least in part, to decreased cardiomyocyte apoptosis. Participation of Mas in ischemia-reperfusion injury was confirmed in Mas knockout mice, which had reduced infarct size relative to mice with normal Mas expression. These results suggest that activation of Mas during myocardial infarction contributes to ischemia-reperfusion injury and further suggest that inhibition of Mas-G(q) signaling may provide a new therapeutic strategy directed at cardioprotection.|
|Tong Zhang; Zhuangjie Li; Huong Dang; Ruoping Chen; Chen Liaw; Thuy-Anh Tran; P Douglas Boatman; Daniel T Connolly; John W Adams|
Related Documents :
|22408024 - Slackness between vessel and myocardium is necessary for coronary flow reserve.
21686644 - Post-mortem evidence of idiopathic left ventricular hypertrophy and idiopathic intersti...
22260254 - Xenon is not superior to isoflurane on cardiovascular function during experimental acut...
6353394 - Systolic time intervals: a review of the method in the non-invasive investigation of ca...
12538124 - Is hybrid coronary revascularization favored by cardiologists or cardiac surgeons?
3779724 - Detection of silent myocardial ischemia in patients with angina using continuous electr...
|Type: Journal Article Date: 2011-10-14|
|Title: American journal of physiology. Heart and circulatory physiology Volume: 302 ISSN: 1522-1539 ISO Abbreviation: Am. J. Physiol. Heart Circ. Physiol. Publication Date: 2012 Jan|
|Created Date: 2011-12-27 Completed Date: 2012-02-14 Revised Date: 2012-05-23|
Medline Journal Info:
|Nlm Unique ID: 100901228 Medline TA: Am J Physiol Heart Circ Physiol Country: United States|
|Languages: eng Pagination: H299-311 Citation Subset: IM|
|Arena Pharmaceuticals Incorporated, San Diego, California, USA.|
|APA/MLA Format Download EndNote Download BibTex|
Apoptosis / drug effects
Cardiotonic Agents / chemistry, pharmacology*
Coronary Circulation / drug effects*
Disease Models, Animal
Dose-Response Relationship, Drug
Drug Inverse Agonism
GTP-Binding Protein alpha Subunits, Gq-G11 / metabolism*
Inositol Phosphates / metabolism
Myocardial Infarction / genetics, metabolism, pathology, physiopathology, prevention & control*
Myocardial Reperfusion Injury / genetics, metabolism, pathology, physiopathology, prevention & control*
Myocardium / metabolism*, pathology
Proto-Oncogene Proteins / antagonists & inhibitors*, genetics, metabolism
RNA, Messenger / metabolism
Receptors, G-Protein-Coupled / antagonists & inhibitors*, genetics, metabolism
Signal Transduction / drug effects*
Type C Phospholipases / metabolism
Ventricular Function, Left / drug effects
|0/Cardiotonic Agents; 0/Inositol Phosphates; 0/Proto-Oncogene Proteins; 0/RNA, Messenger; 0/Receptors, G-Protein-Coupled; 0/proto-oncogene proteins c-mas-1; EC 3.1.4.-/Type C Phospholipases; EC 184.108.40.206/GTP-Binding Protein alpha Subunits, Gq-G11|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study.
Next Document: Impaired blood pressure recovery to hemorrhage in obese Zucker rats with orthopedic trauma.